Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Lanifibranor (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 26 Jul 2018 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2019.
- 26 Jul 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.
- 20 Jun 2018 According to an Inventiva Pharma media release, first patient is expected to be enrolled in the third quarter of 2018 and topline results are expected beginning of 2020.